|
|
| Enbrel |
All Financial Data in US $ (mln) |
|
Word Search (Top 10 - by date)
|
Q3 2013 Marks the End of the Patent Cliff Period
Sanofi
(October 30, 2013)
|
Pfizer Reports Third-Quarter 2013 Results
Pfizer
(October 29, 2013)
|
Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Coherus BioSciences
(October 28, 2013)
|
Amgen's Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
Amgen
(October 22, 2013)
|
Bristol-Myers Squibb to Present Data on Rheumatoid Arthritis Assets at American College of Rheumatology (ACR) 2013 Annual Meeting
Bristol-Myers Squibb
(October 22, 2013)
|
Novartis Delivers Strong Sales Performance in Third Quarter Driven by Growth Products' Momentum; Innovation Newsflow Reinforces Growth Prospects
Novartis
(October 22, 2013)
|
Pfizer Announces Top-Line Results Of The First Two Of Five Phase 3 Clinical Trials Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis
Pfizer
(October 09, 2013)
|
Secukinumab (AIN457) Showed Superiority Over Enbrel® in Clearing Skin, According to Pivotal Novartis Phase III Psoriasis Results at EADV
Novartis
(October 03, 2013)
|
Novartis to Reveal Landmark Phase III Results from Specialty Dermatology Portfolio at Upcoming EADV 2013 Congress
Novartis
(September 30, 2013)
|
Emergent BioSolutions Appoints Barry Labinger as Executive Vice President of the Company and President of Its Biosciences Division
Emergent BioSolutions
(August 16, 2013)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.
|
|
Product Sales Summary 2009/10
|
|
Annual Sales WW - Sales
|
Growth per Year (%)
|
|
Rank1 |
Generic Name
|
Therapeutic Subcategory
|
2010 |
| Enbrel2 |
|
|
|
7,257 |
|
|
|
|
Clinical Trial Coverage: No. of Trials involving Product
|
|
|
|
Welcome
Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.
Explore Evaluate
Partnering
EvaluatePharma® now includes Partnering Opportunities - products available for licensing.
Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.
Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.
Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.
Register to access more FREE content:
- 2011 Product Sales analysis
- Download analysis into Excel
- Search 2 yrs of company press releases
Register for Free Analysis
Register to access more free insights and analysis from Evaluate.
Register Now
|
|
|
|